← Browse by Condition
Medical Condition
chronic myelomonocytic leukemia
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 2, Phase 1, Phase 1, Phase 2
NCT04195633 Phase 2
Recruiting
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Enrollment
60 pts
Location
United States
Sponsor
Fred Hutchinson Cancer Center
NCT05031897 Phase 2
Recruiting
Two Step Haplo With Radiation Conditioning
Enrollment
63 pts
Location
United States
Sponsor
Thomas Jefferson University
NCT05184842 Phase 2
Recruiting
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Enrollment
91 pts
Location
United States
Sponsor
Montefiore Medical Center
NCT07249346 Phase 2
Recruiting
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Enrollment
124 pts
Location
United States
Sponsor
Hannah Choe, MD
NCT06071624 Phase 1
Recruiting
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
Enrollment
30 pts
Location
United States
Sponsor
Huda Salman
NCT05807932 Phase 1, Phase 2
Recruiting
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Enrollment
38 pts
Location
Germany
Sponsor
Heinrich-Heine University, Due...
NCT06111612
Recruiting
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
Enrollment
50 pts
Location
China
Sponsor
Shanghai General Hospital, Sha...